• Galmed disclosed first-time preclinical prostate cancer results for Aramchol combined with Xtandi, with results already presented.
• The combination produced stronger tumor cell killing than Xtandi alone, supporting a potential role in delaying treatment resistance.
• Strategic focus targets Xtandi’s multibillion-dollar franchise as key patents expire in Europe in 2026 and the US in 2027.
• Management framed the regimen as a lifecycle-management option ahead of a planned US price cut starting in 2027.
• Partnering talks are planned based on a recently submitted patent application covering the Aramchol-enzalutamide combination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608170915PR_NEWS_USPR_____LN27154) on August 17, 2026, and is solely responsible for the information contained therein.